JP7795466B2 - モノアシルグリセロールリパーゼ調節因子 - Google Patents

モノアシルグリセロールリパーゼ調節因子

Info

Publication number
JP7795466B2
JP7795466B2 JP2022548400A JP2022548400A JP7795466B2 JP 7795466 B2 JP7795466 B2 JP 7795466B2 JP 2022548400 A JP2022548400 A JP 2022548400A JP 2022548400 A JP2022548400 A JP 2022548400A JP 7795466 B2 JP7795466 B2 JP 7795466B2
Authority
JP
Japan
Prior art keywords
azabicyclo
azaspiro
carbonyl
octan
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512729A (ja
JP2023512729A5 (https=
Inventor
ケー. アメリクス,マイケル
ビー. ベリー,シンシア
ガルシア-レイナガ,パブロ
ゴ ラフォルテザ,ブライアン
ティー. リアング,ジミー
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2023512729A publication Critical patent/JP2023512729A/ja
Publication of JP2023512729A5 publication Critical patent/JP2023512729A5/ja
Application granted granted Critical
Publication of JP7795466B2 publication Critical patent/JP7795466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022548400A 2020-02-10 2021-02-09 モノアシルグリセロールリパーゼ調節因子 Active JP7795466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972484P 2020-02-10 2020-02-10
US62/972,484 2020-02-10
PCT/EP2021/053062 WO2021160602A1 (en) 2020-02-10 2021-02-09 Monoacylglycerol lipase modulators

Publications (3)

Publication Number Publication Date
JP2023512729A JP2023512729A (ja) 2023-03-28
JP2023512729A5 JP2023512729A5 (https=) 2024-02-20
JP7795466B2 true JP7795466B2 (ja) 2026-01-07

Family

ID=74595268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548400A Active JP7795466B2 (ja) 2020-02-10 2021-02-09 モノアシルグリセロールリパーゼ調節因子

Country Status (22)

Country Link
US (2) US11708359B2 (https=)
EP (1) EP4103557B1 (https=)
JP (1) JP7795466B2 (https=)
KR (1) KR20220140581A (https=)
CN (1) CN115066422B (https=)
AR (1) AR121296A1 (https=)
AU (1) AU2021220539A1 (https=)
BR (1) BR112022015116A2 (https=)
CA (1) CA3169988A1 (https=)
CL (1) CL2022002136A1 (https=)
CO (1) CO2022011275A2 (https=)
CR (1) CR20220376A (https=)
DO (1) DOP2022000162A (https=)
EC (1) ECSP22062460A (https=)
IL (1) IL295447A (https=)
JO (1) JOP20220180A1 (https=)
MX (1) MX2022009804A (https=)
PE (1) PE20221576A1 (https=)
PH (1) PH12022552019A1 (https=)
TW (1) TW202140465A (https=)
UY (1) UY39066A (https=)
WO (1) WO2021160602A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140465A (zh) * 2020-02-10 2021-11-01 比利時商健生藥品公司 單醯基甘油脂酶調節劑
CN115362151B (zh) 2020-03-26 2025-02-11 詹森药业有限公司 作为单酰基甘油脂肪酶调节剂的芳基哌啶
MX2022011903A (es) 2020-03-26 2023-01-11 Janssen Pharmaceutica Nv Azaspirociclos como moduladores de monoacilglicerol lipasa.
WO2021191391A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CA3228446A1 (en) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators for use in autism spectrum disorders
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528428A (ja) 2011-09-30 2014-10-27 ヤンセン ファーマシューティカ エヌ.ベー. 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤
WO2018020263A1 (en) 2016-07-29 2018-02-01 Autifony Therapeutics Limited Cyclobutane derivatives as modulators of voltage-gated potassium channels
WO2019065791A1 (ja) 2017-09-29 2019-04-04 武田薬品工業株式会社 複素環化合物
JP2019510026A (ja) 2016-03-31 2019-04-11 武田薬品工業株式会社 複素環化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493637A1 (en) 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
CN112272670B (zh) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
TW202140465A (zh) 2020-02-10 2021-11-01 比利時商健生藥品公司 單醯基甘油脂酶調節劑
CN115362151B (zh) 2020-03-26 2025-02-11 詹森药业有限公司 作为单酰基甘油脂肪酶调节剂的芳基哌啶
MX2022011903A (es) 2020-03-26 2023-01-11 Janssen Pharmaceutica Nv Azaspirociclos como moduladores de monoacilglicerol lipasa.
WO2021191391A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528428A (ja) 2011-09-30 2014-10-27 ヤンセン ファーマシューティカ エヌ.ベー. 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤
JP2019510026A (ja) 2016-03-31 2019-04-11 武田薬品工業株式会社 複素環化合物
WO2018020263A1 (en) 2016-07-29 2018-02-01 Autifony Therapeutics Limited Cyclobutane derivatives as modulators of voltage-gated potassium channels
WO2019065791A1 (ja) 2017-09-29 2019-04-04 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
CR20220376A (es) 2022-09-16
MX2022009804A (es) 2022-09-02
CA3169988A1 (en) 2021-08-19
CN115066422B (zh) 2024-11-22
PH12022552019A1 (en) 2023-11-29
US11708359B2 (en) 2023-07-25
ECSP22062460A (es) 2022-11-30
US20230382902A1 (en) 2023-11-30
JOP20220180A1 (ar) 2023-01-30
EP4103557C0 (en) 2026-02-18
JP2023512729A (ja) 2023-03-28
BR112022015116A2 (pt) 2022-09-27
AU2021220539A1 (en) 2022-10-06
CO2022011275A2 (es) 2022-08-30
DOP2022000162A (es) 2022-10-31
TW202140465A (zh) 2021-11-01
IL295447A (en) 2022-10-01
PE20221576A1 (es) 2022-10-06
EP4103557A1 (en) 2022-12-21
EP4103557B1 (en) 2026-02-18
CL2022002136A1 (es) 2023-02-03
KR20220140581A (ko) 2022-10-18
UY39066A (es) 2021-08-31
WO2021160602A1 (en) 2021-08-19
CN115066422A (zh) 2022-09-16
US20210253565A1 (en) 2021-08-19
AR121296A1 (es) 2022-05-04

Similar Documents

Publication Publication Date Title
JP7795466B2 (ja) モノアシルグリセロールリパーゼ調節因子
JP7777083B2 (ja) モノアシルグリセロールリパーゼ調節因子としてのアザスピロ環化合物
JP7729831B2 (ja) モノアシルグリセロールリパーゼ調節因子としてのアミノシクロブタン
JP7729832B2 (ja) モノアシルグリセロールリパーゼ調節因子としてのアリールピペリジン
US12502378B2 (en) Monoacylglycerol lipase modulators for use in autism spectrum disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251219

R150 Certificate of patent or registration of utility model

Ref document number: 7795466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150